Triple-negative breast cancer patients with primary invasive cancer did not benefit from adjuvant combination chemotherapy plus bevacizumab compared to chemotherapy alone.
A small study analyzing neurocognitive function in women undergoing chemotherapy to treat their breast cancer shows that some of the common cognitive issues experienced by breast cancer patients tend to occur not only post-chemotherapy, but also prior to chemotherapy treatment.
Combining histone deacetylase (HDAC) inhibitors with PARP inhibitors or cisplatin has the potential to be an effective treatment for triple-negative breast cancer, according to preclinical research presented this week at the San Antonio Breast Cancer Symposium.
Combining an investigational agent called PD 0332991 with letrozole improved progression-free survival over letrozole alone in women with advanced estrogen receptor-positive breast cancer, according to a study presented at the San Antonio Breast Cancer Symposium this week.
Breast cancer patients 35 years and younger, even those with luminal-like disease, derive more benefit from neoadjuvant chemotherapy than do older patients, according to a German study presented at SABCS.
SABCS: Increasing Fulvestrant Dose in Advanced ER-Positive Breast Cancer Yields Better Survival, Similar Toxicity
Increasing the dose of fulvestrant from 250 mg to 500 mg yielded a longer median overall survival as well as a lower overall risk of death in women with locally advanced or metastatic estrogen receptor-positive breast cancer, according to results from the CONFIRM trial.
A large cohort study found that black women with early-stage invasive breast cancer were significantly less likely than white patients to undergo the less invasive axillary sentinel lymph node biopsy. Black women also had a higher rate of lymphedema, due largely to that difference in treatment modalities.
Patients who took tamoxifen as adjuvant therapy for ER-positive breast cancer for 10 years had both a reduced risk of recurrence and better overall survival compared to patients who stopped after 5 years, according to results of the ATLAS study presented at SABCS.
To kick off SABCS 2012, we discuss the use of molecular testing for the diagnosis and treatment of breast cancer patients in the clinical setting with Dr. Antonio Wolff of the Kimmel Cancer Center at Johns Hopkins University, one of the presenter's during the "Practical Use of Molecular Profiling" session at this year's symposium.